Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
Background Immune checkpoint inhibitors (ICIs) are the new standard of care in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC). Since tumor response dynamic parameters already shown a strong association with survival outcomes in patients w...
Main Authors: | Alessandra Raimondi, Vittorina Zagonel, Paolo Manca, Chiara Manai, Francesca Daniel, Salvatore Corallo, Michele Prisciandaro, Andrea Spallanzani, Virginia Quarà, Carmen Belli, Marta Vaiani, Maria Di Bartolomeo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-04-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/4/e002501.full |
Similar Items
-
Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency
by: Romain Cohen, et al.
Published: (2021-03-01) -
The Efficacy of Immune Checkpoint Inhibitors as First-line Treatment in Microsatellite-instability- high Metastatic Colorectal Cancer
by: Jong Yoon Lee
Published: (2021-05-01) -
Multi-organ sarcoidosis like reaction mimics metastatic disease in a microsatellite instability-high melanoma patient treated with checkpoint inhibitors
by: Geetha Jagannathan, et al.
Published: (2020-03-01) -
Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment
by: Lin Shen, et al.
Published: (2020-07-01) -
A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype
by: Marina Baretti, et al.
Published: (2021-05-01)